经纤支镜多次分段肺泡灌洗联合rhGM-CSF治疗原发性肺泡蛋白沉积症2例-东南大学学报医学版

经纤支镜多次分段肺泡灌洗联合rhGM-CSF治疗原发性肺泡蛋白沉积症2例

单位：东南大学附属中大医院呼吸与危重症医学科, 江苏南京 210009

分类号：R563.9

出版年·卷·期（页码）：2025·44·第一期（18-22）

摘要：

目的:探讨2例肺泡蛋白沉积症(PAP)治疗的效果及安全性。方法:对本科收治的采用经纤支镜多次分段支气管肺泡灌洗(BAL)联合皮下注射重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)等措施治疗的2例PAP患者进行回顾性分析。结果:2例PAP患者经纤支镜多次分段BAL联合皮下注射rhGM-CSF的治疗效果确切(患者症状消失快,影像学、肺功能、血气分析等检查结果均明显改善)、副作用轻微。结论:经纤支镜多次分段BAL联合rHuGM-CSF治疗PAP安全、方便、可行,近、远期疗效好,是在不具备施行全肺灌洗术条件或患者不适合全肺灌洗术的情况下首选的治疗方法。

Objective: To investigate the therapeutic efficacy and safety in 2 patients diagnosed with pulmonary alveolar proteinosis(PAP). Methods: The clinical data of 2 PAP cases who received the treatment of segmental bronchoalveolar lavage(BAL) in combined with subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor(rhGM-CSF) were analyzed retrospectively. Results: Following the combined treatment, both patients showed significant improvement. There were notable outcomes including rapid alleviation of symptoms, enhanced lung function, and favorable results in CT imaging and blood gas analyses. In addition, the treatment was well-tolerated merely with mild side effects. Conclusion: The combined application of BAL and rhGM-CSF in multiple segments of fiberoptic bronchoscopy is safe, convenient and feasible for treating PAP, which has good short-term and long-term efficacy and is the preferred treatment method when the whole lung lavage operation is not available or the patient is not suitable for the whole lung lavage operation.

参考文献：

[1] ROSEN S H, CASTLMAN B, LIEBOW A A, et al.Pulmonary alveolar proteinosis[J]. N Engl Med, 1958, 258(23):1123-1142.
[2] INOUE Y, TRAPNELL B C, TAZAWA R, et al.Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan[J]. Am J Respir Crit Care Med, 2008, 177(7):752-762.
[3] STANLEY B, LIESCHKE G J, GRAIL D, et al.Granulucyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology[J]. Proc Nail Acad Sci USA, 1994, 91(12):5592-5596.
[4] 陈露露, 张艳秋, 邱玉英, 等.肺泡蛋白质沉积症106例临床分析[J]. 南京医科大学学报(自然科学版), 2018, 38(6):804-806.
[5] CHAULAGAIN C P, PILICHOWSKA M, BRINCKERHOFF L, et al.Secondary pulmonary alveolar proteinosis in hematologic malignancies[J]. Hematol Oncol Stem Cell Ther, 2014, 7(4):127-135.
[6] 中国医师协会呼吸医师分会病理工作委员会, 上海市医师协会病理科医师分会胸部病理学组.肺泡蛋白沉积症细胞学病理诊断中国专家共识[J]. 临床与实验病理学杂志, 2023, 39(4):385-391.
[7] SHAH P L, HANSELL D, LAWSON P R, et al.Pulmonary alveolar proteinosis:clinical aspects and current conceptson pathogenesis[J]. Thorax, 2000, 55(1):67-77.
[8] CAMPO I, LUISETTI M, GRIESE M, et al.Whole lung lavage therapy for pulmonary alveolar proteinosis:a global survey of current practices and procedures[J]. Orphanet J Rare Dis, 2016, 11(1):115.
[9] PILONI D, CAMPO I.Current management strategies and the potential of inhaled GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis[J]. Expert Opin Orphan Drugs, 2019, 7:117-123.
[10] 汪嘉琦, 海冰, 杨嫄.肺泡蛋白沉积症诊治研究进展[J]. 中国临床医学, 2022, 29(4):696-700.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录